Payment overview · 2025
General Payments
$1,947.20
122 reported records · 24 companies
Healthcare provider profile · identity verified
Samuel John Olsen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ETOWAH, TN · NPI 1760448591
Verified facts
What the public records show
CMS Open Payments records show Samuel John Olsen, MD received $1,947.20 in general payments during 2025 across 122 reported records.
ABBVIE INC. accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Brilinta, Eliquis, Entresto, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 752 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $222.26 | 11.4% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $198.60 | 10.2% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $193.64 | 9.9% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $165.56 | 8.5% | 16 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $146.06 | 7.5% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.43 | 7.4% | 12 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $116.58 | 6.0% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$91.38 | 4.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.88 | 4.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $78.59 | 4.0% | 4 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $64.53 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.03 | 3.2% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.59 | 3.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.20 | 2.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.58 | 2.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.73 | 2.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.94 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.62 | 1.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.19 | 1.4% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $24.74 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.39 | 0.8% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $16.30 | 0.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.10 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.28 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,947.20 | 122 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $159.92 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $146.06 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.00 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $141.00 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $124.98 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $119.75 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $119.75 | 10 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $116.58 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $109.66 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $100.37 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $100.37 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $93.26 | 6 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $91.38 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $78.59 | 4 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $64.53 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $63.03 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $63.03 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.34 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.34 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $59.59 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.20 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.72 | 8 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $29.94 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.19 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.68 | 2 | 2025 |
Source payment records
|
|||||
| JUXTAPID Normalized: juxtapid |
Drug | Chiesi USA, Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 53 | exact normalized | Medicare Part D |
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 752 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 86 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 113 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 122 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 21 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
38 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
122 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
53 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
752 | 64 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1687 | 191 |
| Potassium Chloride | Potassium Chloride | 901 | 91 |
| Furosemide | Furosemide | 899 | 81 |
| Gabapentin | Gabapentin | 768 | 100 |
| Eliquis | Apixaban | 752 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 751 | 157 |
| Losartan Potassium | Losartan Potassium | 709 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 663 | 142 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 602 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 600 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 577 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 565 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 523 | 53 |
| Ezetimibe | Ezetimibe | 489 | 136 |
| Omeprazole | Omeprazole | 456 | 92 |
| Famotidine | Famotidine | 417 | 85 |
| Tradjenta | Linagliptin | 371 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 336 | 75 |
| Sucralfate | Sucralfate | 323 | 20 |
| Montelukast Sodium | Montelukast Sodium | 301 | 79 |
| Buspirone Hcl | Buspirone Hcl | 296 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 289 | 51 |
| Tramadol Hcl | Tramadol Hcl | 288 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 287 | 71 |
| Alprazolam | Alprazolam | 278 | 42 |
| Lisinopril | Lisinopril | 271 | 71 |
| Januvia | Sitagliptin Phosphate | 270 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 69 |
| Carvedilol | Carvedilol | 263 | 57 |
| Mirtazapine | Mirtazapine | 259 | 50 |
| Divalproex Sodium | Divalproex Sodium | 249 | 14 |
| Alendronate Sodium | Alendronate Sodium | 241 | 39 |
| Lorazepam | Lorazepam | 239 | 21 |
| Metformin Hcl | Metformin Hcl | 234 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 227 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 220 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 200 | 44 |
| Trazodone Hcl | Trazodone Hcl | 188 | 42 |
| Sertraline Hcl | Sertraline Hcl | 179 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 43 |
| Metformin Hcl Er | Metformin Hcl | 164 | 37 |
| Ondansetron Hcl | Ondansetron Hcl | 161 | 60 |
| Simvastatin | Simvastatin | 157 | 31 |
| Allopurinol | Allopurinol | 154 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 153 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 14 |
| Fenofibrate | Fenofibrate | 131 | 30 |
| Mounjaro | Tirzepatide | 122 | 18 |
| Donepezil Hcl | Donepezil Hcl | 120 | 29 |
| Clonazepam | Clonazepam | 116 | 13 |
| Levetiracetam | Levetiracetam | 116 | 16 |
| Farxiga | Dapagliflozin Propanediol | 114 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 114 | 11 |
| Jardiance | Empagliflozin | 113 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 25 |
| Benazepril Hcl | Benazepril Hcl | 104 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 44 |
| Prednisone | Prednisone | 94 | 48 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 89 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 30 |
| Entresto | Sacubitril/Valsartan | 86 | suppressed |
| Pregabalin | Pregabalin | 86 | 21 |
| Baclofen | Baclofen | 83 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 76 | suppressed |
| Ozempic | Semaglutide | 74 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 73 | 11 |
| Xarelto | Rivaroxaban | 73 | 16 |
| Digoxin | Digoxin | 70 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 69 | 15 |
| Repatha Sureclick | Evolocumab | 69 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 21 |
| Atenolol | Atenolol | 68 | 16 |
| Celecoxib | Celecoxib | 68 | 12 |
| Clonidine Hcl | Clonidine Hcl | 68 | 14 |
| Diazepam | Diazepam | 67 | suppressed |
| Synthroid | Levothyroxine Sodium | 67 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | 27 |
| Meloxicam | Meloxicam | 66 | 22 |
| Spironolactone | Spironolactone | 66 | 14 |
| Carbamazepine | Carbamazepine | 65 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 15 |
| Belsomra | Suvorexant | 62 | suppressed |
| Valsartan | Valsartan | 58 | 14 |
| Warfarin Sodium | Warfarin Sodium | 58 | 14 |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Bumetanide | Bumetanide | 56 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Ketoconazole | Ketoconazole | 56 | 14 |
| Lovastatin | Lovastatin | 56 | suppressed |
| Repatha Pushtronex | Evolocumab | 56 | 14 |
| Trulicity | Dulaglutide | 56 | 14 |
| Lubiprostone | Lubiprostone | 55 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | 12 |
| Linzess | Linaclotide | 54 | 12 |
| Mitigare | Colchicine | 54 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 53 | 53 |
| Acetic Acid | Acetic Acid | 53 | suppressed |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Estradiol | Estradiol | 52 | 12 |
| Latanoprost | Latanoprost | 52 | suppressed |
| Olanzapine | Olanzapine | 52 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | suppressed |
| Finasteride | Finasteride | 49 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 47 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 12 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 44 | suppressed |
| Vascepa | Icosapent Ethyl | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 12 |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | 11 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Prolia | Denosumab | 38 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 35 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 35 | suppressed |
| Indapamide | Indapamide | 34 | suppressed |
| Colchicine | Colchicine | 33 | 13 |
| Lactulose | Lactulose | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Nystatin | Nystatin | 32 | 17 |
| Cefuroxime | Cefuroxime Axetil | 31 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 19 |
| Fluconazole | Fluconazole | 27 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 24 |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Klor-Con 10 | Potassium Chloride | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Aptiom | Eslicarbazepine Acetate | 22 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 18 |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 20 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 18 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 15 |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Forteo | Teriparatide | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 14 | suppressed |
| Teriparatide | Teriparatide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Moexipril Hcl | Moexipril Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Tymlos | Abaloparatide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,947.20 · 122 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BRILINTA, CAPLYTA, COMIRNATY, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FFRct, FREESTYLE LIBRE 3, GVOKE HYPOPEN, General - Erectile Dysfunction, INSPIRE, JARDIANCE, JUXTAPID, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TARPEYO, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error